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Abstract
The hereditary hyperferritinaemia–cataract syndrome (HHCS) is characterised by an autosomal dominant cataract
and high levels of serum ferritin without iron overload. The cataract develops due to L-ferritin deposits in the lens and
its pulverulent aspect is pathognomonic. The syndrome is caused by mutations within the iron-responsive element of
L-ferritin. These mutations prevent efficient binding of iron regulatory proteins 1 and 2 to the IRE in L-ferritin mRNA,
resulting in an unleashed ferritin translation. This paper reviews all 31 mutations (27 single nucleotide transitions and
four deletions) that have been described since 1995. Laboratory test showing hyperferritinaemia, normal serum iron
and normal transferrin saturation are indicative for HHCS after exclusion of other causes of increased ferritin levels
(inflammation, malignancy, alcoholic liver disease) and should prompt an ophthalmological consultation for diagnostic
confirmation. Invasive diagnostics such as liver biopsy are not indicated. HHCS is an important differential diagnosis of
hyperferritinaemia. Haematologists, gastroenterologists and ophthalmologists should be aware of this syndrome to
spare patients from further invasive diagnosis (liver biopsy), and also from a false diagnosis of hereditary haemo-
chromatosis followed by venesections. Patients diagnosed with HHCS should be counselled regarding the relative
harmlessness of this genetic disease, with early cataract surgery as the only clinical consequence.
Keywords: ferritin, hyperferritinaemia, cataract, iron overload, genetic, eye lens
Cellular and body iron regulation
Iron is essential for a variety of biological functions at
the cellular and systemic level, such as oxygen trans-
port and the catalytic activity of many enzymes;1
however, the specific chemical properties of iron as a
transition metal also render it potentially toxic for
cells and tissues. In the presence of reactive oxygen
species (ROS), iron catalyses the generation of highly
reactive hydroxyl radicals (Fenton/Haber–Weiss reac-
tions) that damage membrane lipids, proteins and
nucleic acids.2 Considering that ROS are inevitable
by-products of aerobiosis, organisms have to control
iron concentrations tightly at the systemic and at the
cellular level to satisfy metabolic needs but minimise
iron toxicity. A complex network has evolved in
mammals, assuring safe and balanced iron trafficking.
Efficient absorption mechanisms exist for various
forms of nutritional iron in the proximal small intes-
tine (1 mg/day in humans).3 While the reticuloen-
dothelial system is crucial for iron recycling and
redistribution, the liver serves as an iron storage
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organ. Figure 1 schematically depicts important path-
ways in iron trafficking in a virtual cell. Iron can
enter the cell only in the reduced form (ferrous iron,
Fe2þ), but is stored or bound to carrier proteins only
in the ferric iron state (Fe3þ). Several enzymes have
been identified to oxidise/reduce iron, such as the
ferrireductase Dcytb and hephaestin in intestinal cells
or ceruloplasmin at the basolateral site of most cells.
Iron circulates in higher organisms bound to trans-
ferrin (Tf). It is internalised by cells via the ubiquitous
transferrin receptor 1 (TfR1) – the major iron uptake
protein. Expression of TfR2 – a second transferrin
receptor – is limited to erythroid, hepatocellular and
duodenal cells. The TfR–Tf complex is internalised
by endocytosis, iron is then released, reduced and
eventually transferred to the cytoplasm by the divalent
metal transporter 1 (DMT1). An impaired interaction
of TfR1 and/or TfR2 with a mutated human haemo-
chromatosis (HFE) protein causes the most common
monogenic hereditary disease in humans (hereditary
haemochromatosis), which eventually leads to iron
overload and tissue damage in several organs.4,5 The
central interchangeable form of iron is called the labile
iron pool (LIP), which represents a loosely chelated
form of iron that can undergo toxic redox reactions.6
Cellular iron can be safely stored in ferritin, a
multi-subunit protein of heavy- (H) and light- (L)
chains, or it can be redistributed within the cells for
major utilisation pathways like Fe-S-cluster or haem
synthesis.
At the systemic level, iron can be exported from
macrophages, duodenal cells, hepatocytes and some
cells of the central nervous system via ferroportin
to undergo systemic circulation. This export is
regulated by the antimicrobial peptide hepcidin,
which inhibits iron efflux by interacting with ferro-
portin, leading to ferroportin internalisation and
degradation.7,8 At present, hepcidin that is secreted
from liver cells is generally considered as the ‘sys-
temic iron sensor’ in higher organisms.3,9
Figure 1. The role of ferritin in iron homeostasis. A virtual cell is shown, demonstrating the major cellular functions of iron uptake
(TfR1 and -2, DMT1), export (ferroportin), storage (ferritin) and utilisation (eg haem synthesis). The LIP represents a chelated form of
cytosolic iron that undergoes redistribution but also toxic side reactions. Hepatic hepcidin – the major systemic regulator – blocks
iron export via ferroportin, while cytoplasmic IRPs coordinate cellular iron homeostasis by regulating proteins such as TfR1 and ferritin
at the post-transcriptional level. Ferritin is the major iron storage protein and is mainly localised in hepatocytes and cells of the
reticuloendothelial system. Connections between cellular and systemic iron metabolism are highlighted by hatched grey boxes.
TfR1, transferrin receptor 1
DMT1, divalent metal transporter 1
LIP, labile iron pool
IRP, iron-regulatory protein
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Ferritin as an iron storage molecule
Excess non-haem iron is stored in ferritin. Ferritin
is a protein with a molecular mass of approximately
900 kDa which is present in virtually every cell. All
human ferritins consist of 24 subunits of H and L
chain ferritin. H-ferritin (21 kDa) is encoded on
chromosome 11, while the L-ferritin sequence (19
kDa) is localised on chromosome 19. Both subunits
together form a spherical shell around a cavity.
Within this cavity, up to 4,500 iron atoms can be
safely stored (ie without the possibility of reacting
with ROS and generating hydroxyl radicals). Fe2þ
is oxidised by the ferroxidase centre to insoluble
hydroxyferric complexes through consumption of
O2 or hydrogen peroxide (H2O2). Iron storage by
ferritin is a reversible process, and during periods
of iron starvation, ferritin readily releases iron
whenever needed. Although ferritin always consists
of 24 subunits, the ratio of H- to L-ferritin is vari-
able (depending on the type of tissue), creating
several isoferritins. H- and L-ferritin differ in terms
of their function: while H-ferritin is responsible for
iron storage and carries the ferroxidase activity
needed to sequester iron, it is L-ferritin that exerts a
regulatory function, owing to the presence of acidic
groups that facilitate iron oxidation and hydrolysis.
Ferritins containing exclusively H-chains oxidise
iron approximately ten-fold faster than ferritins rich
in L-ferritin.10 By contrast, addition of even a small
number of L-subunits to the ferritin molecule accel-
erates the transfer of iron from the ferroxidase centre
to the iron core. This step is rate limiting and
L-ferritin therefore improves the overall iron seques-
tering process.11 Ferritins rich in H-ferritin have
been found in the heart and brain and are believed
to exert iron-segregating and antioxidant functions,
whereas spleen and liver ferritins contain a larger
proportion of L-ferritin and thus serve as iron
stores, releasing iron on demand.12
Serum ferritin as a marker for
body iron stores
Small amounts of ferritin are also present in the
serum. A large body of evidence suggests that
circulating ferritin levels parallel the amount of iron
stored in the liver. This is only true for the physio-
logical state and true iron overload, however, since
other pathological conditions—such as inflammatory,
autoimmune and malignant diseases—can lead to a
disproportionate elevation of serum ferritin.13,14
Although clinicians have been using ferritin as a
marker for body iron storage for more than three
decades, little is known about the source of serum
ferritin. Serum ferritin is iron poor, resembles
L-ferritin immunologically and is thought to contain
glycosylated (G) ferritin.15 Reticuloendothelial cells
(ie macrophages16) and hepatocytes17 are the major
iron-storing cell types in the body, and both contrib-
ute to extracellular ferritin production. Initially, it
was thought that serum ferritin results from cellular
leakage, but in vitro studies have demonstrated that
L-ferritin can be targeted for glycosylation via the
regular secretory pathway. This is an active process
during translation, despite the lack of a conventional
signal sequence.17
Post-transcriptional control of ferritin
synthesis is iron dependent
Iron availability is the main regulator of cellular
ferritin synthesis. After ferritin was cloned in 1986,18
it was quickly learnt that it is mainly regulated
at the translational level, controlled by a
157-nucleotide-containing leader sequence in the
50-untranslated region of ferritin mRNA.19 This
leader sequence contains the so-called iron-responsive
element (IRE), a sequence of approximately 50
nucleotides which forms a hairpin-like secondary
structure and allows the iron-regulatory protein (IRP)
to bind. There are two IRPs in the human body,
IRP-1 and IRP-2. They are both able to sense iron,
although via distinct mechanisms.20–22 In the pres-
ence of iron, IRP-1 changes its conformation by
assembling a cubane iron–sulphur cluster [4Fe–4S],
loses its RNA-binding activity and acts a cytosolic
aconitase.20,23,24 By contrast, IRP-2 undergoes iron-
dependent proteasomal degradation.25,26 Under con-
ditions of intracellular iron depletion, both IRPs can
bind IRE with high affinity, prevent binding of the
translation initiation complex and thus block ferritin
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translation (Figure 2). Both types of ferritin are regu-
lated by an IRE, although data from heterozygous
H-ferritin knockout mice suggest that there might be
different iron thresholds at which L- and H-ferritin
respond.27 IREs have not only been identified in fer-
ritin mRNA. They are also products of other genes,
such as TfR1, which contains a series of five IREs in
the 30-untranslated region. IRP/IRE binding to the
TfR1 IREs in iron deficiency increases the stability
of TfR1 mRNA and, finally, iron uptake.28
Interestingly, IRP-1 is not only affected by iron levels
but also by various reactive oxygen and nitrogen
species, such as H2O2, superoxide and hypochlorous
acid and NO.29 Comparable with iron depletion, low
levels of H2O2 rapidly activate IRP-1 for binding to
IRE, even at the whole-organ level.22,30
Hyperferritinemia Cataract
Syndrome (HHCS) is due to
uncontrolled translation of L-ferritin
Until the mid-1990s, hyperferritinaemia was
thought primarily to be associated with iron over-
load, inflammation and malignancy. In 1995, two
groups in Italy and France independently discovered
families with hyperferritinaemia of unexplained
aetiology that co-segregated with autosomal-
dominant cataract at an unusually young age.31,32
These patients had been initially misdiagnosed with
hereditary haemochromatosis, although no iron
overload had been found in liver biopsies and they
developed iron-deficiency anaemia after repeated
venesections. The novel clinical entity was even-
tually named as hyperferritinaemia–cataract syn-
drome (HHCS). Table 1 lists the typical clinical
criteria for HHCS diagnosis. The chromosomal
location of this disorder was found to be on
chromosome 19, close to L-ferritin,31 and Bonneau
et al. first discussed a potential involvement of the
IRE in L-ferritin.32 Shortly thereafter, both groups
Figure 2. Post-transcriptional control of ferritin synthesis by the IRP/IRE network. Iron depletion activates IRP-1 and -2 for binding
to the IRE in the 50-untranslated region of ferritin mRNA. This IRP–IRE interaction prevents translation of ferritin and eventually
decreases ferritin protein levels.
IRP, iron-regulatory protein
Table 1. Clinical criteria of hyperferritinaemia–cataract syndrome.
† High and constant levels of serum ferritin unresponsive to
iron depletion
† No signs of iron overload (normal soluble serum iron and
transferrin saturation)
† Normal blood cell counts and normal transaminases
† Familial cataract with phenotypic pulverulent appearance
† No relevant clinical symptoms apart from visual impairment
by cataract
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identified causative point mutations within the IRE
of L-ferritin, although the mutations were not iden-
tical but located on neighbouring nucleotides
within the same region (Paris-1 mutation: 40A.
G,33 Verona-1 mutation: 40G . C).34 Protein–
RNA interaction assays finally confirmed that the
mutated IRE does indeed have a drastically reduced
affinity for IRP. The disrupted IRE–IRP inter-
action uncouples L-ferritin synthesis from iron avail-
ability and leads to uncontrolled and sustained
L-ferritin translation.33
Spectrum of mutations in the HHCS
Since the first description of HHCS (OMIM
#600886), a total of 31 mutations have been
described within the IRE region of L-ferritin in
various countries. The geographical distribution of
mutations described to date primarily suggests a
stronger co-localisation with iron metabolism/hae-
mochromatosis research centres than with prevalence
of HHCS. A complete list (updated in September
2009) of all underlying mutations and patients pub-
lished to date is given in Table 2. Table 2 also shows
the different nomenclatures for each of the mutation
sites, the patients’ countries of origin, and the
numbers of families and patients per publication.
Twenty-seven of these mutations are single nucleo-
tide transitions and four are deletions of 2–29 base
pairs. The single nucleotide transitions in particular
indicate which part of the IRE is critical for an effi-
cient and functional IRE–IRP interaction. The
most important sequences are a highly conserved
hexanucleotide at the terminal loop, a bulge with an
unpaired cytidin, and the upper stem of the hairpin
(Figure 3). The lower stem seems to be less prone to
mutations that could cause HHCS. Molecular
models published by Lachlan et al. showed how point
mutations in the L-ferritin IRE can distort the IRE
hairpin structure.46 An even more detailed analysis of
IRP–IRE binding disturbances by various mutations
was published by Allerson et al. in 1999, where they
analysed thermodynamic changes in IRE structure
and IRP–IRE interactions in different mutations75
and were able to correlate the clinical severity of
HHCS with the severity of IRE–IRP disturbance.
Ophthalmological presentation of
the cataract in HHCS
Although the cataract is the only clinical manifes-
tation in HHCS, it is still unknown to many
ophthalmologists and remains undiagnosed even
after ophthalmological consultation for cataract
surgery. The descriptions of HHCS cataract vary
considerably. A comprehensive study of cataract fea-
tures in several families affected by HHCS using
the slit-lamp and retro-illumination technique has
been performed by Craig and colleagues.45
According to this study, cataract morphology in
HHCS families is highly distinctive and consistent
but varies with age at onset and severity. The
primary characteristics are the appearance of axial
and peripheral white flecks and small crystalline
aggregates. Other opacities are small cortical vacu-
oles which are translucent but easily visible on
retro-illumination. Craig and colleagues even con-
cluded that cataract morphology should be
sufficient to suspect HHCS.45 Figure 4 shows a
typical cataract in a patient with a 32G . A
mutation representing all of the above-mentioned
features. Due to the lack of larger studies, it
remains unclear whether or not the cataract in
HHCS patients is congenital or develops in early
infanthood. Girelli et al. described a child
with hyperferritinaemia at birth, in whom no
cataract appeared during follow-up for one year.76
Similar observations have been reported by
others.64
After unravelling the pathomechanism of HHCS
and collecting increasing numbers of HHCS
families, it became clear that the clinical severity
with regard to serum ferritin levels, and visual
impairment due to cataract correlated with the type
of mutation. Cazzola and co-workers showed that
mutations in the highly conserved hexanucleotide
region (eg at position 40 or 41) caused a severe
cataract, while mutations around the bulge with
unpaired cytidine (eg position 32) caused mild
cataract. In addition, mutations in the lower stem
of IRE caused only asymptomatic cataract (double
mutation at positions 18 and 22).36 Molecular
models published by Lachlan et al. showed how
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point mutations in the L-ferritin IRE can distort
the IRE hairpin structure.46
It should be noted that not only the extent of
the cataract, but also the local distribution of the
nuclear and cortical opacities affect visual impair-
ment. In the case of the first German family to be
added to the database, recently published by the
present authors, the degree of impairment of the
central visual axis determined the timing of cataract
surgery, which varied considerably from the age of
14 to 57 years, although all family members had an
identical single point mutation.42
Clinical relevance of HHCS
Thus far, most patients with HHCS have been ident-
ified in the course of a check-up for high serum fer-
ritin. Many patients are initially misdiagnosed with
hereditary haemochromatosis and treated with
venesections that lead to rapid iron depletion and
iron-deficiency anaemia. Haematologists, gastroen-
terologists and ophthalmologists should therefore be
aware of HHCS to prevent false diagnosis and need-
less invasive diagnostics, such as liver biopsy, but also
harmful therapeutic approaches such as venesection.
The laboratory triad of hyperferritinaemia, normal
Figure 3. Mutations causing hyperferritinaemia–cataract syndrome (HHCS) in the iron-responsive element (IRE) of L-ferritin. The IRE
of L-ferritin forms a hairpin-like structure. Most of the mutations that cause HHCS discovered so far are located in the upper stem and
the conserved hexanucleotide of the IRE. Single nucleotide transitions are depicted by grey arrows, and the number of the nucleotide
deletions are represented by brackets. An extensive overview of all mutations can be found in Table 2.
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serum iron and normal transferrin saturation is
indicative of HHCS after exclusion of other causes of
increased ferritin levels (inflammation, malignancy,
alcoholic liver disease) and should prompt an oph-
thalmological consultation. HHCS patients do not
show increased transaminases or any signs of inflam-
mation (elevated C-reactive protein or increased
white blood cell count). After diagnosing HHCS,
patient counselling should focus on the relative
harmlessness of this genetic disease, with early cata-
ract surgery as the only clinical consequence.
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